Idenix Pharmaceuticals (IDIX) Tops Q3 EPS by 20c

Idenix Pharmaceuticals (NASDAQ: IDIX) reported Q3 EPS of $0.03, $0.20 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $32.3 million, versus $2.6 million reported last year.

2012 Financial Guidance

At September 30, 2012, Idenix's cash and cash equivalents totaled $251.9 million. The Company expects that its current cash and cash equivalents will be sufficient to sustain its operations through at least March 31, 2014. This guidance assumes no milestone payments, license fees, reimbursement for development programs and no financing activities.

For earnings history and earnings-related data on Idenix Pharmaceuticals (IDIX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
• Investing.com’s stocks of the week
• RBC Capital Reiterates Outperform Rating on Verisk Analytics (VRSK)